KRAS and non-small cell lung carcinoma: Amodio et al. reported reversed KRAS inhibitor resistance and an increased cell-death ratio in CC and NSCLC patients where a KRAS inhibitor and anti-EGFR antibody (cetuximab) were applied collectively [73].